Montelukast,
does it really help with Improved allergic-rhinitis and asthma symptoms in children and adults?
research showsMontelukast is rated C. Multiple trials and meta-analyses show real but small symptom benefits versus placebo in rhinitis and asthma, while intranasal corticosteroids are more effective for rhinitis and inhaled corticosteroids are more effective for persistent asthma. In 2020 the FDA required its strongest Boxed Warning for serious neuropsychiatric events including agitation, depression, and suicidal thoughts or actions.
ads claimIn Korea it is commonly prescribed to children for rhinitis, cough, and asthma and may be perceived as an easy oral allergy medicine. Common prescribing does not make it first-line for uncomplicated rhinitis, and mood, sleep, and behavior changes require monitoring in children too.
Useful facts when choosing a product
- Montelukast is a prescription cysteinyl-leukotriene CysLT1-receptor antagonist.
- Depending on age and formulation, 4-mg granules or chewables, 5-mg chewables, or 10-mg tablets are used once daily according to labeling.
- It is not a rescue medicine for an acute asthma attack and must not replace or stop inhaled corticosteroids without clinical direction.
- The FDA Boxed Warning includes serious neuropsychiatric events such as agitation, aggression, nightmares or sleep disturbance, depression, and suicidal thoughts or actions.
What the research actually shows
The 2020 rhinitis meta-analysis found placebo effects of −0.12 for daytime nasal symptoms and −0.09 for nighttime symptoms. The 3.4% figure came from a separate 2006 meta-analysis and must not be attributed to the 2020 citation. Symptoms are treatment targets, but the effect is small and intranasal fluticasone was superior.
Why this is classified as C (45)
Treatment-target symptoms improve, but effects of −0.12 daytime and −0.09 nighttime are small and inferior to intranasal corticosteroids, yielding C with 45 points on efficacy evidence alone; the FDA warning does not set the grade.
Counterpoint. It remains a possible adjunct or alternative for selected patients who cannot use standard treatment or have coexisting rhinitis and asthma.
Rejudgment record. Cross-check applied — Accepted symptom benefits over placebo but applied C because effects are small and inferior to intranasal corticosteroids for rhinitis and inhaled corticosteroids for asthma
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved allergic-rhinitis symptoms | C | Better than placebo but inferior to intranasal corticosteroids. |
| Reduced asthma symptoms and exacerbations | C | Effective but inferior to inhaled corticosteroids. |
| Superiority to intranasal or inhaled corticosteroids | D | Active-comparator meta-analyses instead show inferiority. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Krishnamoorthy M et al. 2020 | Systematic review and meta-analysis of allergic-rhinitis trials | 15 | Academic study; no reported external funding | Daytime and nighttime nasal symptoms | Small placebo effects, DNS −0.12 and NNS −0.09, and inferior to intranasal fluticasone. | Key rhinitis synthesis |
| Castro-Rodriguez JA, Rodrigo GJ. 2010 | Systematic review and meta-analysis of pediatric asthma trials | 3,757 | Academic research | Exacerbations, lung function, and symptoms | Inhaled corticosteroids were superior to montelukast. | Asthma active-comparator evidence |
| U.S. FDA 2020 safety communication | Regulatory safety review and Boxed Warning | U.S. FDA | Neuropsychiatric events | Required the strongest warning and restricted rhinitis use. | Key safety evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Montelukast x symptom improvement in pediatric and adult allergic rhinitis and asthma — Evidence Grade C·45. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/montelukast-allergic-rhinitis-asthma-symptom-control/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.